Dion H Zappe
Overview
Explore the profile of Dion H Zappe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brook R, Kaciroti N, Bakris G, Dahlof B, Pitt B, Velazquez E, et al.
J Am Heart Assoc
. 2018 Jan;
7(1).
PMID: 29301757
Background: The ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension) trial demonstrated that combination therapy using amlodipine, rather than hydrochlorothiazide, in conjunction with benazepril provided...
2.
Izzo Jr J, Zappe D, Jia Y, Hafeez K, Zhang J
J Cardiovasc Pharmacol
. 2017 Mar;
69(6):374-381.
PMID: 28338503
We compared the systolic blood pressure (SBP)-lowering efficacy and safety of crystalline valsartan/sacubitril (LCZ696, an angiotensin receptor blocker-neprilysin inhibitor) 400 mg daily against valsartan (320 mg once daily) alone or...
3.
Weinberg M, Weinberg A, Cord R, Zappe D
J Renin Angiotensin Aldosterone Syst
. 2017 Jan;
2(1_suppl):S196-S198.
PMID: 28095227
The optimal doses of angiotensin-converting enzyme inhibitors (ACE-I) and/or angiotensin II receptor blockers (ARBs) for maximal reduction in urinary protein excretion are not known. Moreover, beneficial effects from ARBs, such...
4.
Williams B, Cockcroft J, Kario K, Zappe D, Brunel P, Wang Q, et al.
Hypertension
. 2017 Jan;
69(3):411-420.
PMID: 28093466
Effective treatment of systolic hypertension in elderly patients remains a major therapeutic challenge. A multicenter, double-blind, randomized controlled trial with sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, was conducted...
5.
Izzo Jr J, Jia Y, Zappe D
J Clin Hypertens (Greenwich)
. 2016 Sep;
19(2):143-150.
PMID: 27587277
The effects of race and age on 24-hour mean ambulatory systolic blood pressure (maSBP) responses to sequential 4-week periods of angiotensin receptor blocker therapy (valsartan [VAL] 160 mg/d then 320...
6.
Weber M, Bloch M, Bakris G, Weir M, Zappe D, Dahlof B, et al.
J Clin Hypertens (Greenwich)
. 2016 Apr;
18(4):299-307.
PMID: 27060568
To evaluate the effects of achieved systolic blood pressure (SBP) during treatment on cardiovascular (CV) outcomes, the authors measured event rates of a composite primary endpoint (CV death or nonfatal...
7.
Mancia G, Kjeldsen S, Zappe D, Holzhauer B, Hua T, Zanchetti A, et al.
Eur Heart J
. 2015 Nov;
37(12):955-64.
PMID: 26590384
Aims: Recent hypertension guidelines recommend that also in high cardiovascular (CV) risk, hypertensive patients blood pressure (BP) is lowered to <140/90 mmHg as no evidence is available supporting the lower...
8.
9.
Skoglund P, Svensson P, Asp J, Dahlof B, Kjeldsen S, Jamerson K, et al.
J Clin Hypertens (Greenwich)
. 2014 Dec;
17(2):141-6.
PMID: 25529596
Pulse pressure (PP) is an independent risk factor for cardiovascular (CV) disease and death but few studies have investigated the effect of antihypertensive treatments in relation to PP levels before...
10.
Zappe D, Crikelair N, Kandra A, Palatini P
J Hypertens
. 2014 Sep;
33(2):385-92.
PMID: 25259546
Objective: Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP)...